TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lyell Immunopharma ( (LYEL) ) has issued an update.
On September 15, 2025, Charles Newton announced his resignation as Chief Financial Officer of Lyell Immunopharma, effective October 31, 2025. The company will search for a replacement and has entered a consulting agreement with Newton to provide services until April 30, 2026.
The most recent analyst rating on (LYEL) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s overall stock score reflects a challenging financial situation with no revenue and ongoing losses, balanced by positive corporate events and moderate technical indicators. The recent funding and promising clinical trial data are significant positives, but the company’s valuation remains low due to negative earnings.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma operates in the biopharmaceutical industry, focusing on developing cell therapies for cancer treatment.
Average Trading Volume: 76,491
Technical Sentiment Signal: Hold
Current Market Cap: $252.2M
For detailed information about LYEL stock, go to TipRanks’ Stock Analysis page.